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Abstract
Background: The development of a safe, effective, reversible, non-hormonal contraceptive method for men has
been an ongoing effort for the past few decades. However, despite significant progress on elucidating the function
of key proteins involved in reproduction, understanding male reproductive physiology is limited by incomplete
information on the genes expressed in reproductive tissues, and no contraceptive targets have so far reached
clinical trials. To advance product development, further identification of novel reproductive tract-specific genes
leading to potentially druggable protein targets is imperative.
Results: In this study, we expand on previous single tissue, single species studies by integrating analysis of publicly
available human and mouse RNA-seq datasets whose initial published purpose was not focused on identifying
male reproductive tract-specific targets. We also incorporate analysis of additional newly acquired human and
mouse testis and epididymis samples to increase the number of targets identified. We detected a combined total
of 1178 genes for which no previous evidence of male reproductive tract-specific expression was annotated, many
of which are potentially druggable targets. Through RT-PCR, we confirmed the reproductive tract-specific expression
of 51 novel orthologous human and mouse genes without a reported mouse model. Of these, we ablated four
epididymis-specific genes (Spint3, Spint4, Spint5, and Ces5a) and two testis-specific genes (Pp2d1 and Saxo1) in
individual or double knockout mice generated through the CRISPR/Cas9 system. Our results validate a functional
requirement for Spint4/5 and Ces5a in male mouse fertility, while demonstrating that Spint3, Pp2d1, and Saxo1 are
each individually dispensable for male mouse fertility.
Conclusions: Our work provides a plethora of novel testis- and epididymis-specific genes and elucidates the
functional requirement of several of these genes, which is essential towards understanding the etiology of male
infertility and the development of male contraceptives.
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Background
The world human population reached nearly eight bil-
lion people in August 2019. This number continues to
rise and is predicted to reach nearly ten billion by the
year 2050 [1]. The increasing need to promote family
planning through the development of reliable contracep-
tive options available to both men and women is widely
recognized. Currently there are numerous contraceptive
options available to women; however, identification of a
safe, non-hormonal contraceptive option for men is still
an ongoing challenge. Although several different fertility
control alternatives for men have been investigated,
none are currently clinically approved for use. Our un-
derstanding of the mechanisms underlying male repro-
ductive physiology is still at an early stage as the
identification and elucidation of the function of key re-
productive proteins is still an ongoing effort. Identifying
druggable protein targets expressed in the male repro-
ductive tract has been the focus of numerous studies
dedicated to the development of male contraception.
The mammalian epididymis is a segmented organ
comprised of a single, highly coiled tubule with func-
tionally and morphologically distinct regions that can be
subdivided most simplistically into a proximal, central,
and distal region, conventionally named the caput, cor-
pus, and cauda regions, respectively [2]. As mammalian
spermatozoa transit through the epididymis, they ac-
quire the ability to recognize and fertilize an egg, proper-
ties that they did not possess upon exiting the testis [3].
Considering its essential role, the epididymis—in
addition to maturing germ cells of the testis and sperm-
atozoa—is a prime target for the development of a male
contraceptive. To advance progress towards the develop-
ment of a non-hormonal male contraceptive, several pre-
vious high-throughput studies have been published that
identified a number of human, mouse, and rat genes as
testis-specific or epididymis-specific [2, 4–9]. In 2003,
Schultz et al. conducted the first study to identify male
reproductive tract-specific genes using microarrays.
Through Affymetrix-based genome-wide gene-
expression analysis of meiotic- and post-meiotic sper-
matogenic cells, together with parallel analysis of avail-
able data from the NCBI UniGene database, the authors
identified 271 mouse genes as testis-specific, which in-
cluded genes with both known and unknown function at
the time [4]. In the following 5 years, through two add-
itional microarray-based studies of rat testes and purified
rat testicular cells, Johnston et al. identified 58 [5] and
398 [8] additional or overlapping genes as testis-
specific. In 2014, as part of the continued effort to iden-
tify novel contraceptive targets, the newer RNA-seq-
based transcriptomics methodology was utilized identify-
ing 364 human genes as testis-specific [9]. Together with
antibody-based protein profiling, many of these genes
were characterized in terms of the spermatogenic cell
populations showing expression [9].
The first high-throughput transcriptomics study to iden-
tify epididymis-specific genes was a 2005 mouse epididy-
mal transcriptome study, in which RNA isolated from
each of the 10 epididymal segments was analyzed by
microarray analysis, identifying 75 epididymis-specific
genes with distinct patterns of segmental gene regulation
[2]. Later in 2007, additional transcriptome profiling utiliz-
ing whole genome microarrays resulted in identification of
77 previously unreported epididymis-specific transcripts in
the mouse [6] and 110 epididymis-specific transcripts in
the rat [7]. A significant number of the identified mouse
and rat genes in these studies were not known at the time,
and only the probe identification numbers were presented.
When evaluating potential druggability in a target-
based drug discovery process, one must consider the
protein properties that are required for safe and effective
inhibition. Among the most significant is tissue expres-
sion specificity to minimize potential adverse effects,
protein function and whether protein activity or inter-
action with other proteins is potentially druggable, se-
quence similarity to closely related paralogs that may be
ubiquitously expressed, and whether genetically manipu-
lated animal models demonstrate a functional require-
ment for the target of interest [10]. Several noteworthy
review publications have mentioned numerous genes
whose critical functions, high expression, and specificity
to the testes or epididymides make them viable non-
hormonal male contraceptive targets [11–18]. However,
among the identified genes, a significant number either
(1) are required for fertility, but are expressed in non-
reproductive tissues, or (2) are reproductive tract-
specific, but, when disrupted, lead to subfertility [10]. In
either case, both are ineffective and highly undesirable
outcomes for a potential male contraceptive target.
Therefore, the identification of additional novel male re-
productive tract-specific genes would allow for further
advances to be made in the quest to develop an effective
and safe non-hormonal male contraceptive.
In this study, 21 newly acquired and 243 previously pub-
lished human and mouse RNA-seq datasets [9, 19–26]
were processed in parallel through a custom bioinformat-
ics pipeline designed to identify novel reproductive tract-
specific and reproductive tract-enriched transcripts. Add-
itional databases obtained from Illuminating the Drug-
gable Genome [27], Mouse Genome Informatics [28], and
Ensembl BioMart [29] were utilized to stratify the results
into subgroups based on protein druggability and on the
availability of a mouse model. Numerous reproductive
tract-specific and reproductive tract-enriched, potentially
druggable targets for which no published mouse model
exists, congruent in expression across both mouse and hu-
man datasets were identified through our analysis and
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verified through conventional polymerase chain reaction
(PCR). We present the data in a manner that should be
most relevant and of substantial interest to the male
contraceptive development field since identification of
new targets worthy of consideration for further functional
analysis in a knockout animal model and potential drug
targeting continues to be of vast importance.
Through our results, we identified four novel
epididymis-specific genes (Spint3, Spint4, Spint5, and
Ces5a) and two novel testis-specific genes (Pp2d1 and
Saxo1) worthy of functional validation in an animal
model. Through the CRISPR/Cas9 system, we generated
four individual gene knockouts (Spint3, Ces5a, Pp2d1,
and Saxo1) and one double knockout mouse model
(Spint4/5) revealing an essential requirement for Spint4
and Spint5 in male mouse fertility, and the potential util-
ity of pursuing SPINT4 in humans as a non-hormonal
contraceptive target.
Results
Study approaches and data
Despite significant advances in our understanding of the
human and rodent testis and epididymis transcriptome,
mostly through microarray-based studies, no prior stud-
ies have utilized purified human testis cells for the iden-
tification of human testis-specific transcripts, no prior
studies have utilized the more state-of-the-art RNA-seq-
based transcriptomics methodology for analysis of hu-
man epididymis-specific transcripts, and no prior studies
have utilized RNA-seq analysis of rodent reproductive
tissues or cells to identify rodent reproductive tract-
specific transcripts. To address these gaps in knowledge,
and to increase the number of identified reproductive
tract-specific genes in both species using the most rele-
vant high-throughput transcriptomics methodology, we
analyzed in parallel on a custom bioinformatics pipeline
a large number of published and newly acquired human
and mouse RNA-seq datasets. One hundred and sixty-
two previously published human and 81 previously pub-
lished mouse RNA-seq datasets were retrieved from the
Sequence Read Archive (SRA). The SRA value for each
sample is listed in Additional file 1: Table S1 and Add-
itional file 1: Table S2. We also generated 12 new human
and 9 new mouse reproductive tissue RNA-seq samples
(GEO Accession GSE150854). The final dataset is com-
prised of 3 new and 5 previously published human testis
datasets [9], 27 previously published purified human
germ cell datasets [23, 24], 6 previously published puri-
fied human Sertoli cell datasets [23, 26], 9 new and 6
previously published human epididymis segment data-
sets [21], 6 previously published mouse testis datasets
[19], 9 new mouse epididymis datasets, 10 previously
published purified mouse germ cell datasets [22, 25],
and 3 previously published purified mouse Sertoli cell
datasets [20]. An additional 118 previously published
datasets contributed to the 26 non-reproductive human
tissues [30] and 62 previously published datasets con-
tributed to the 14 non-reproductive mouse tissues [19].
Figure 1a, b summarizes all the samples acquired for the
study.
We performed a principal component analysis to
visualize the variation in the samples after correcting for
batch effects. Human reproductive and non-reproductive
tissues grouped according to sample type. The repro-
ductive tissue samples clustered by tissue type whether
or not they were newly generated or acquired from the
SRA (Fig. 1c). Mouse data showed a similar variation in
the samples based on the tissue type (Fig. 1d). For both
human and mouse reproductive tissues, samples sepa-
rated by whether or not the RNA-seq was performed on
isolated cells or the whole tissue. Epididymal tissue was
distinct from testis tissue in both human and mouse
(Fig. 1c, d).
To identify potential male reproductive tract-specific
drug candidates, we analyzed the aggregated RNA-seq
data to find genes that were statistically significant in ex-
pression when compared to the non-reproductive tissue
that had the maximum expression for that gene. This
gene list was then further refined by filtering for genes
that were lowly expressed in the non-reproductive tissue
that had the maximum expression for that gene (TPM
less than or equal to 1.0 for human; TPM less than or
equal to 2.0 for mouse). Finally, this TPM filtered list
was then filtered for the genes that had a reproductive
tissue or cell expression value greater than or equal to
10.0 TPM for human, or 8.0 TPM for mouse (Fig. 2a).
Across all the reproductive tissues, 720 candidate genes
were identified in the human and 1304 candidate genes
were identified in the mouse samples (Fig. 2b,
Additional file 2: Fig. S1). Additional file 3: Table S3 and
Additional file 4: Table S4 summarize the differential
fold change, identity of the non-reproductive tissue with
maximal gene expression based on the differential gene
analysis, FDR, average and standard deviation TPM ex-
pression values, and log2 CPM gene expression value for
the human and mouse samples, respectively. The results
from the FDR and TPM expression value filtering for
the human and mouse samples are summarized in
Additional file 5: Table S5 and Additional file 6: Table
S6, respectively. Additional file 5: Table S5 and
Additional file 6: Table S6 report the log2 fold change
for the reproductive tissue or cell of interest compared
to the tissue with maximal gene expression. The genes
identified in Additional file 5: Table S5 and
Additional file 6: Table S6 pass the filters in at least one
of the reproductive tissues or cells of interest. In
Additional file 5: Table S5 and Additional file 6: Table
S6, a value of zero for a given gene and fold expression
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Fig. 1 (See legend on next page.)
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comparison indicates that for that comparison, the gene
did not pass the filters. The majority of genes were
downregulated in the reproductive tissue of interest
compared to the maximal gene expressing non-
reproductive tissue (Additional file 7: Fig. S2). From the
analysis, the majority of the candidate genes that passed
the FDR and TPM filters were identified in the testis- or
sperm-related cells in both human and mouse samples
(Additional file 7: Fig. S2).
The majority of candidate genes identified in our
screen that were testis-specific were already identified by
the Human Protein Atlas [9] and/or our reanalysis of
(See figure on previous page.)
Fig. 1 Summary of the human and mouse RNA-seq samples used in the identification of novel male reproductive tract-specific drug targets. The
RNA-seq samples used in the human (a) and mouse (b) analyses are schematically shown. Principal component analysis was performed on the
human (c) and mouse (d) non-reproductive and reproductive samples separately. The colors of the circles next to the tissues listed in a and b
correspond to the colors used in the circles for the PCA in c and d. Sample size (N) values in red and/or black denote the number of new (red)
and previously published (black) samples included in our analysis.
Fig. 2 Identification of candidate drug male reproductive gene targets. a Diagrammatic representation of overall methodology used to identify
reproductive tract-specific candidate genes in humans (720 genes) and in mice (1062 genes). The maximum gene expression was determined
across all the non-reproductive tissue samples for each gene for a reproductive tissue or cell sample of interest. Genes were then filtered for
significance using a false discovery rate (FDR) of less than or equal to 0.05 based on the differential gene expression analysis for the non-
reproductive tissue with maximum gene expression and reproductive tissue or cell sample of interest. Genes that passed the FDR filter were
filtered such that the average TPM expression value of the maximum expressing non-reproductive tissue was less than or equal to 1.0 TPM and
the average TPM expression value of the reproductive tissue or cell of interest was greater than or equal to 10.0 TPM. b Diagrammatic
representation of the number of human and mouse candidate genes in terms of (1) the number of orthologs in the opposite species, (2) the
number of genes previously or not previously identified in a prior transcriptomics-based drug target report, (3) the availability and phenotypic
outcome of any reported mouse models, and (4) the number of novel genes without a reported mouse model congruent across both species.
The main value in each bubble represents the total number of candidate genes identified regardless of tissue or cell identified in. The numbers in
parentheses comprise the total number of candidate genes that are either epididymis-specific or specific to testis and epididymis, but not testis
and/or testis cell-specific only.
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the HPA testis datasets (Additional file 8: Fig. S3 and
Additional file 9: Table S7). Thirty-six out of the 91
genes that were identified across all the human epididy-
mis tissue were also identified by the human combined
(newly acquired and previously published datasets) testis
candidate gene list. Finally, the majority of the candidate
genes, 300, identified from the combined newly gener-
ated and previously published human testis datasets
were shared with genes identified from the various testis
cell datasets. We identified more candidate genes in the
newly generated human epididymis tissues compared to
previously published data: 19 out of 54 genes were
unique to the newly generated caput samples compared
to only 1 out of 36 genes which was unique to the previ-
ously published samples, 19 out of 75 genes were unique
in the newly generated corpus samples compared to 12
out of 68 genes which were unique to the previously pub-
lished corpus samples, and 33 genes were unique to the
newly generated cauda samples compared to 2 genes in
the previously published cauda data with no overlap be-
tween the two cauda gene lists (Additional file 8: Fig. S3
and Additional file 9: Table S7). There were 117 candidate
genes that overlapped between the newly generated hu-
man testis samples and mouse testis sample gene lists,
while there were 134 candidate genes that overlapped be-
tween the previously published human testis sample and
mouse testis sample gene lists (Additional file 8: Fig. S3
and Additional file 9: Table S7). Across all human epididy-
mis tissue samples, including the newly generated and
previously published samples, there were 16 genes in com-
mon with the combined list of candidate genes across all
the mouse epididymis tissue samples. There was a small
overlap between the human and mouse samples when the
newly generated human caput, corpus, and cauda tissues
were individually compared to the mouse caput, corpus,
and cauda tissues; there was an overlap of 10, 12, and 4
for the caput, corpus, and cauda, respectively
(Additional file 8: Fig. S3 and Additional file 9: Table S7).
This trend was continued for the candidate gene lists de-
rived from the previously published human caput, corpus,
and cauda samples when compared to the candidate gene
list from the mouse caput, corpus, and cauda, with 7, 10,
and 4 genes in common for the caput, corpus, and cauda
comparisons, respectively (Additional file 8: Fig. S3 and
Additional file 9: Table S7). Additional file 9: Table S7 de-
tails the genes that are unique and in common for each of
the comparisons.
To assess the potential usefulness of the candidate
genes identified in each human reproductive tissue as
drug targets, we assigned the genes to a protein family
(i.e., GPCR or ion channel). The majority of identified
genes were not from a traditional drug target family like
kinases or enzymes. The testis and germ cell datasets
provided the most potential targets while the epididymis
datasets provided the fewest (Additional file 10: Fig.
S4A). The protein family classification for each candi-
date gene identified in each reproductive tissue is de-
tailed in Additional file 11: Table S8. The majority of the
candidate genes do not have a reported mouse model
(Additional file 10: Fig. S4B). Additional file 12: Table S9
summarizes mouse model availability for each candidate
gene identified from human reproductive tissues or cells.
Figure 3 shows the complete list of novel human genes
without a reported mouse model as identified in each of
the respective cell and/or tissue datasets. Digital PCRs
(heatmap) and conventional PCRs demonstrating ex-
pression of a subset of the novel human reproductive
tract-specific genes without a reported mouse model
that we identified are shown in Figs. 4 and 5, respect-
ively. Additional file 13: Fig. S5 shows the complete list
of previously identified human genes that remain with-
out a reported mouse model as identified in each of the
respective cell and/or tissue datasets. Additional file 14:
Fig. S6 shows the complete list of male reproductive
tract-specific human genes for which a previously gener-
ated mouse model shows male infertility phenotype, as
identified in each of the respective cell and/or tissue
datasets.
Reproductive tract-specific genes identified through
human datasets
Through our bioinformatics analysis of previously pub-
lished and newly acquired RNA-seq datasets, we identi-
fied a total of 720 genes as reproductive tract-specific in
humans (Fig. 2). Of these genes, 122 genes do not have a
mouse gene ortholog, while 598 genes have a mouse
gene ortholog (Fig. 2). Of those with a mouse gene
ortholog, 477 have a single gene ortholog (324 have the
same symbol in mouse, while 153 have a different
symbol in mouse), while 121 have two or more ortholo-
gous mouse genes. Seventy-six human genes had 2–3
orthologous mouse symbols, 36 genes had 4–10 ortholo-
gous mouse symbols, and 9 genes (FAM205A, KRTA
P10-6, MAGEA10, OR2AG1, PRAMEF11, PRAMEF2,
SSX2, SSX3, and SSX4B) had greater than 10 ortholo-
gous mouse symbols (11–93 symbols) (Additional file 5:
Table S5). Of the 720 human genes that we identified as
male reproductive tract-specific, 435 have not been pre-
viously identified in a transcriptomics-based male repro-
ductive tract-specific study [2, 4–9]. The sum of our
human data confirms the findings of 232 out of 364
genes from Djureinovic et al. [9]. After re-identification
of gene symbols from reported Affymetrix IDs and con-
sideration of orthologous genes (mouse to human and
rat to human), our human data confirm the findings of
19 out of 39 genes from Johnston et al. [5], 77 out of
176 genes from Schultz et al. [4], 5 out of 32 genes from
Johnston et al. [6], 36 out of 253 genes from Johnston
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et al. [2], 4 out of 58 genes from Johnston et al. [8], and
3 out of 19 genes from Jelinsky et al. [7]. Of the 598
genes that have a mouse gene ortholog, 346 have not
been previously identified as male reproductive tract-
specific, and of these, 233 human genes currently lack
mouse phenotype information based on data obtained
from Ensembl BioMart, MGI, IMPC, and NCBI.
Human testis-specific
Three hundred and eighty-six genes were identified as
testis-specific through either the reanalysis of Djureino-
vic et al. testis datasets (377 genes identified), analysis of
our de novo testis datasets (322 genes identified), or
both (Additional file 5: Table S5). Three hundred and
thirteen genes were congruent across both datasets,
while 64 genes were uniquely identified through our re-
analysis of Djureinovic et al.’s datasets and only 9 genes
[AC136352.4, ANKRD20A1, ANKRD62, FAM230A,
GGTLC2, IQCM, POTEC, PRNT, and UTF1] were
uniquely identified through our de novo datasets
(Additional file 5: Table S5). Interestingly, of the 377
genes we identified through Djureinovic et al.’s reana-
lyzed datasets, 143 were not previously identified in their
report [9] or any of the other previous reports [2, 4–8].
Of these 143 genes, we randomly verified 21 of these
genes as testis-specific in humans through conventional
PCR (Fig. 5). We also verified through RT-PCR an add-
itional 15 genes—such as ALLC, CDKL3, COX7B2,
OR2H1, and SPPL2C—that had been identified through
previous studies (Additional file 15: Fig. S7). Of the 386
genes identified through either testis datasets, 150 have
not been previously identified; of these, 117 genes have
one or more mouse orthologs; and of these, 76 genes are
lacking reported phenotype information. Of the 76 novel
genes lacking a reported mouse model, 7 genes encode
enzymes (ADAM20, CPA5, DUSP21, NAA11, PLSCR2,
PRSS38, and TRIML1), 6 encode transcription factors
(BHMG1, FOXR2, PRDM9, TGIF2LY, ZNF560,
ZNF729), 2 encode transporters (SLC22A14, SLC25A52),
and 61 encode proteins of unknown drug target type
Fig. 3 Two hundred and thirty-three novel human reproductive tract-specific genes that each have mouse orthologous genes but with no
reported knockout mouse models. The listed genes were identified in one or more datasets as indicated in the Venn diagram. Underlined genes
were also identified in our studies as reproductive tract-specific in mouse (109 genes). Genes written in blue encode either enzymes, kinases,
GPCRs, oGPCRs, transporters, transcription factors, or proteins involved in epigenetic regulation (74 genes). Genes written in dark red were
identified in both testis (testis and/or testis cell) and epididymis (10 genes).
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(such as ETDB, SMIM36, BEND2, BTG4, CNBD1,
DPPA2, EFCAB5, ERICH6, FTHL17, IQCM, MROH2B,
MS4A5, OOSP2, PNMA6E, PPP4R3C, RBMXL3, RTL9,
SPDYE4, SPEM2). All of these genes are listed in Fig. 3,
and many of these genes are listed in Figs. 4, 5, and/or 6.
To the best of our knowledge, no prior studies have
utilized purified human testis cells for the identification
of human testis-specific transcripts. Through our ana-
lysis, we identified 291 genes as human testis-specific
through one or more of the human germ cell datasets,
but not through either of the human testis datasets
(Additional file 5: Table S5). Seventy-six genes were
identified exclusively through one or more of the five
human spermatogonia datasets (genes such as ANP32D,
C13orf42, DSCR4, OR13G1, OR2D2, OR52E4, SSX2,
TLE7), while 18 genes were identified exclusively
through the human spermatocyte datasets (genes such
as H2BFM, MAGEB17, MAGEB18, OR2B6, TCP10, and
ZNF709) and 79 genes were identified exclusively
through the human spermatid datasets (genes such
as AC013269.1, CLEC20A, OR7E24, PRAMEF2, SPAT
A31A3, TMEM191C, ZNF679). Thirty-four genes
were identified through all three cell types’ datasets
(genes such as CCDC166, ELOA2, FAM47A, HEAT
R9, and SPATA31A1). Many of these genes are listed
in Figs. 3, 4, 5, and/or 6.
Of the 291 genes identified as human testis-specific
through one or more of the human germ cell datasets,
252 genes have not been previously identified, 201 of
which have one or more equivalent mouse orthologs
with 139 of these genes having not been knocked out in
mouse. Of these 139 novel genes with no mouse model,
8 encode enzymes (GLT6D1, PRSS48, SATL1, SULT6B1,
TMPRSS7, TPTE2, TRIML2, and TTLL8), 1 encodes an
epigenetic protein (TAF1L), 6 encode GPCRs (GPR156,
TAS2R13, TAS2R30, TAS2R46, TAS2R50, VN1R2), 1 en-
codes a kinase (CDKL4), 33 encode oGPCRs (such as
OR2D3, OR3A2, OR52E5, OR8G5, OR10J1, and
Fig. 4 Representative novel reproductive tract-specific human (a) and mouse (b) genes without a reported mouse model. The listed genes were
identified through our studies as reproductive tract-specific in both humans and mice. The digital PCR (heatmap) depicts the average transcripts
per million (TPM) value per tissue per gene from the indicated human and mouse RNA-seq datasets as processed in parallel through our
bioinformatics pipeline. The data was obtained from 264 published and newly acquired datasets. White = 0 TPM, Black ≥ 30 TPM. The expression
profile of the human and mouse housekeeping genes, GAPDH and Eif3l, is included as reference. For data obtained from published datasets,
superscript values succeeding the sample names reference the publications as follows: 1 (Djureinovic et al. [9]; Fagerberg et al. [30]), 2 (Guo et al.
[24]), 3 (Zhu et al. [23]), 4 (Kumar et al. [26]), 5 (Browne et al. [21]), 6 (Consortium et al. [19]), 7 (Helsel et al. [25]), 8 (da Cruz et al. [22]), and 9
(Zimmermann et al. [20]).

















































































































































































































































































Fig. 5 RT-PCR confirmation of reproductive tract specificity in both humans (a) and mice (b). The genes listed in this figure are novel as identified
through our studies and without a reported mouse model. Humans do not have an equivalent protein-coding equivalent to mouse Spint5. GAPD
H and Hprt are included as housekeeping genes.
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OR14A2), 6 encode transcription factors (NKX2-4,
ZNF99, ZNF648, ZNF705B, ZNF705G, and ZNF709), 3
encode transporters (ABCC12, SLC35G3, SLC35G5), and
81 encode proteins of unknown drug target type (such
as AC008073.3, AC113554.1, AKNAD1, AL049634.2,
DNLZ, ERVW-1, ETDA, FBXW10, FER1L5, LMNTD1,
LRRC72, NMS, PRR23A, PRR23B, PRR23C, PXT1,
RFPL4B, and SSX4B). Many of these genes are listed in
Figs. 3, 4, 5, and/or 6.
FAM236A (Figs. 3 and 4) and OBP2B met candidate
threshold through our analysis of human testes datasets
but did not meet candidate threshold from any of the
germ cell or Sertoli cell datasets, indicating potential ex-
pression in peritubular myoid cells, Leydig cells, or other
cell outside of the seminiferous epithelium. FAM36A has
not been previously identified, and neither mouse ortho-
logs (1700011M02Rik, Gm9112) have been knocked out.
OBP2B was previously identified through Djureinovic
et al. [9] and Johnston et al. [6]; however, of the equiva-
lent mouse orthologs (Lcn4, Obp2a, Obp2b), only Obp2a
has been knocked out revealing abnormal coat/hair pig-
mentation [31].
ISM2 and MAGEC2 were identified through both hu-
man Sertoli cell datasets, while also identified through
testis and/or germ cell datasets. Both genes have been
previously identified (ISM2 [8], MAGEC2 [9]). Ism2
knockout mice display non-reproductive phenotypes [9].
Consistent with this finding, our mouse data do not
identify Ism2 as reproductive tract-specific in mice.
MAGEC2 lacks a mouse ortholog for functional ana-
lysis in mice.
Human Sertoli cell-specific
KRTAP2-3, KRTAP4-12, LHX9, and PSG5 were identi-
fied through one or both human Sertoli cell datasets but
were not identified through any of the testis or germ cell
Fig. 6 Three hundred and two novel mouse genes with human orthologs without a reported mouse model. The listed genes were identified in
one or more mouse datasets as indicated in the Venn diagram. Underlined genes were also identified through our studies as reproductive tract-
specific in human (111 genes). Genes written in blue encode either enzymes, kinases, GPCRs, oGPCRs, transporters, transcription factors, or
proteins involved in epigenetic regulation (60 genes). Genes written in dark red were identified in both testis (testis and/or testis cell) and
epididymis (14 genes).
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datasets indicating Sertoli cell-specific expression in the
testes (Additional file 5: Table S5). None of these genes
have been previously identified as reproductive tract-
specific in humans although LHX9 and PSG5 have
mouse orthologs that have been knocked out [32–37].
Human KRTAP2-3 has mouse orthologs Krtap5-2,
Gm4559, Gm40460, and Gm45618, and human KRTA
P4-12 has mouse orthologs Krtap4-7 and Gm11555;
none of these mouse orthologs have been knocked out
(Fig. 3 and Additional file 5: Table S5).
Psg5 knockout mice display non-reproductive pheno-
types [32–36]; however, Lhx9 knockout mice display ab-
sent testes and sterility due to an essential requirement
for Lhx9 during mouse gonad formation [37]. A Lhx9-
GFPCreER knock-in mouse line—generated by
knocking-in GFPCreER at the endogenous Lhx9 locus—
crossed with the Rosa26-tdTomato reporter mouse line
revealed Cre recombinase activity in retinal amacrine
cells, developing limbs, testis, hippocampal neurons,
thalamic neurons, and cerebellar neurons [38]. Thus,
Lhx9 is not reproductive tract-specific in mice. Our
mouse data confirm this finding.
Human epididymis-specific
To the best of our knowledge, no prior studies have uti-
lized RNA-seq for analysis of human epididymis-specific
transcripts. Through our studies, we identified 39 genes
as human epididymis-specific through one or more of
the human epididymis segment datasets that were not
identified through any of the other human male repro-
ductive tissue or cell datasets, indicating true epididymis
specificity (Additional file 5: Table S5). Of these 39
genes identified as human epididymis-specific, 29 genes
have not been previously identified, 24 of which have
equivalent mouse orthologs with 16 of these genes hav-
ing not been knocked out in mouse. Of these 16 novel
human epididymis-specific genes with no mouse model,
1 encodes an enzyme-related gene (SPINT3) and the
remaining 15 encode proteins of unknown drug target
type (such as ACTBL2, BSPH1, MSLNL, SPAG11A,
SPAG11B, WFDC10A, and WFDC9) (Fig. 3).
Seven genes were identified through our de novo se-
quenced human epididymis segment datasets that were
not identified through our reanalysis of the human epi-
didymis segment datasets by Browne et al.; two of these
genes are considered novel without mouse models:
DEFB104A and DEFB104B (Fig. 3, Additional file 5: Table
S5, and Additional file 9: Table S7). Meanwhile, five genes
were identified through our reanalysis of the human epi-
didymis segment datasets by Browne et al. that were not
identified through our de novo-sequenced human epididy-
mis segment datasets; two of these genes are considered
novel without mouse models: ACTBL2 and MSLNL (Fig. 3,
Additional file 5: Table S5, and Additional file 9: Table S7).
Specific to human testis and epididymis
Fifty-two genes met the criteria for identification as
epididymis-specific through one or more of the human
epididymis segment datasets, while also being identified
as reproductive tract-specific through one or more of
the testes, germ cell, and/or Sertoli cell datasets
(Additional file 5: Table S5). Thus, these targets are not
epididymis-specific per se, but may be desirable potential
male contraceptive targets considering their broader tar-
get availability. Of these 52 genes identified as human
male reproductive tract-specific and epididymis-
expressed, 20 genes have not been previously identified,
15 of which have one or more equivalent mouse ortho-
logs with 11 of these genes having not been knocked out
in mouse. All 11 of these novel genes with no mouse
model encode proteins of unknown drug target type
(AL163195.3, CCDC168, CCNB3, DEFB121, DEFB134,
EPPIN-WFDC6, KRTAP2-3, MAGEA11, PNMA6E,
SPEM2, TEX44) (Fig. 3 and Additional file 5: Table S5).
Since model organisms other than mice may be of
interest for the future functional study of human
genes—especially those for which no known mouse
ortholog exists—we list novel reproductive tract-specific
human genes without a mouse ortholog in
Additional file 16: Fig. S8, which may be of interest for
generating null rat or marmoset models [39]. Digital
PCR (heatmap) demonstrating expression of a subset of
these novel human reproductive tract-specific genes
without mouse orthologs is shown in Additional file 17:
Fig. S9.
Genes identified through mouse datasets
Through our bioinformatics analysis of previously pub-
lished and newly acquired mouse RNA-seq datasets, we
identified a total of 1062 genes as reproductive tract-
specific in mice. Of these genes, 303 genes do not have a
human gene ortholog, while 759 genes do (Fig. 2). Of
those with a human gene ortholog, 632 have a single
ortholog (451 with the same gene symbol in human; 181
with a different symbol), while 127 mouse genes have
two or more ortholog human genes (Fig. 2). Ninety-two
mouse genes have 2–3 orthologous human symbols, 16
genes have 4–10 orthologous human symbols, and 19
genes (such as 1700080O16Rik, Ankrd36, Fam90a1b,
Gm15319, Magea10, Pramel1, Spdye4a, Spdye4b, and
Zfy1) have greater than 10 orthologous human symbols
ranging anywhere from twelve to twenty-six symbols
(Additional file 6: Table S6). Of the 1062 mouse genes
that we identified as male reproductive tract-specific in
mouse, 743 have not been identified in a previous tran-
scriptomics-based study [2, 4–9]. The sum of our mouse
data confirms the findings of 150 out of 271 mouse
genes from Schultz et al. [4], 7 out of 54 mouse genes
from Johnston et al. [2], and 6 out of 23 mouse genes
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from Johnston et al. [6] (Additional file 18: Table S10).
Of the 759 mouse genes that have a human ortholog
equivalent, 482 have not been previously identified as
male reproductive tract-specific, and of these, 302 genes
currently lack mouse phenotype information based on
data obtained from Ensembl BioMart, MGI, IMPC, and
NCBI (Fig. 6). Digital PCR (heatmap) demonstrating ex-
pression of a subset of the novel mouse reproductive
tract-specific genes with human orthologs and no re-
ported mouse model, and with human reproductive tract
enrichment, is shown in Fig. 7.
Seventeen novel genes without mouse models
(8030474K03Rik, Fthl17b, Fthl17c, Fthl17d, Fthl17e,
Fthl17f, Gm15262, Gm18336, Magea3, Magea4, Magea5,
Magea6, Magea8, Mageb2, Xlr5a, Xlr5b, and Xlr5c) were
identified through the mouse ID4+ spermatogonia data-
sets that were also identified as spermatogonia-specific
through the human datasets (BEND2, BX276092.9,
FAM9A, FTHL17, MAGEA3, MAGEA4, MAGEA6,
MAGEB6, and PNMA6E) and were not identified
through either mouse or human testis datasets, indicat-
ing restricted expression in spermatogonia, spermato-
gonial stem cells, or both (Additional file 5: Table S5
and Additional file 6: Table S6). Eight genes
(1700080O16Rik, Ccnb3, Gm21964, Gm4779, Pet2,
Prr23a1, Prr23a2, and Prr23a3) were identified through
the mouse ID4+ spermatogonia datasets, genes whose
human orthologs—CCNB3, DCAF8L1, MAGEA10,
MAGEA11, MAGEA12, MAGEA9, MAGEA9B, PRR23A,
PRR23B, PRR23C, and TLE7—were also identified
through the human spermatogonia datasets. Since these
genes were also identified through mouse, human, or
both species’ respective testis datasets, this indicates ei-
ther strong expression in the spermatogonia compart-
ment or expression outside of and in addition to the
spermatogonia compartment.
Mouse Sertoli cell-specific
Twenty-two genes were identified as mouse Sertoli cell-
specific as they were not otherwise identified as repro-
ductive tract-specific through our analysis of mouse tes-
tes or germ cell datasets (ENCODE Project Consortium
testes and Helsel et al.’s ID4+ germ cell datasets)
(Additional file 6: Table S6). Of these 22 genes, 18 have
human orthologs; of these 18 genes, 17 are novel and
not previously identified as male reproductive tract-
Fig. 7 Novel reproductive tract-specific mouse genes with human reproductive tract enrichment, without a reported mouse model. The digital
PCR (heatmap) depicts the average transcripts per million (TPM) value per tissue per gene from the indicated human (a) and mouse (b) RNA-seq
datasets. The data was obtained from 264 published and newly acquired datasets. White = 0 TPM, Black ≥ 30 TPM. The expression profile of the
human and mouse housekeeping genes, GAPDH and Eif3l, is included as reference. For data obtained from published datasets, superscript values
are as previously mentioned.
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specific; of these 17 genes, 7 have not been previously
knocked out in the mouse (C1ql2, Gm45015, Mageb18,
Mycs, Shc4, Sowahd, and Tmsb15b2); and of these 7
genes, 2 genes (Gm45015 and Mageb18) were identified
with human orthologs (PNMA6E and MAGEB18) that
were also identified through our human analysis as
human reproductive tract-specific (Additional file 5:
Table S5 and Additional file 6: Table S6).
Unlike the limited number of reproductive tract-specific
genes we identified through human Sertoli cell-specific
datasets, a considerable number of genes—202 mouse
genes—were identified as reproductive tract-specific
through analysis of Zimmermann et al.’s mouse postnatal
day 35 Sertoli cell datasets that were also identified
through either the mouse testis datasets, mouse ID4+
germ cell datasets, or both (Additional file 6: Table S6). Of
these 202 genes, 160 have one or more human orthologs;
of these 160 genes, 54 are novel and not previously identi-
fied as male reproductive tract-specific; of these 54 genes,
36 have not been previously knocked out in the mouse;
and of these 36 genes, 16 (1700011L22Rik,
1700011M02Rik, 1700018B08Rik, 1700042G07Rik,
Ankrd36, Ankrd60, Etd, Gm39566, Gm6657, Gm9112,
Magea10, Spata31d1b, Tcp10c, Tex44, Tex48, and Wfdc9)
were identified with human orthologs that were also iden-
tified through our analyses as human reproductive tract-
specific (Fig. 6, Additional file 5: Table S5, and
Additional file 6: Table S6).
Mouse epididymis-specific
To the best of our knowledge, published RNA-seq data
of mouse whole epididymis or epididymis segments does
not exist, for the identification of epididymis-specific
transcripts or otherwise. Therefore, we isolated caput,
corpus, and cauda segments from adult (postnatal day
60) B6/129 mice and subjected the RNA to sequencing.
Sixty-six genes were identified as mouse epididymis-
specific as they were not identified as mouse male repro-
ductive tract-specific through our reanalysis of the EN-
CODE Project Consortium testis datasets, Helsel et al.’s
ID4+ germ cell datasets, or Zimmermann et al.’s mouse
postnatal day 35 Sertoli cell datasets (Additional file 6:
Table S6). Of these 66 genes, 48 have human orthologs;
of these 48 genes, 34 are novel and not previously identi-
fied as male reproductive tract-specific; of these 34
genes, 17 have not been previously knocked out in the
mouse (Ascl4, Bsph1, C1s2, Clec18a, Cyp2j13, Cyp4a30b,
Defb42, Gm45826, Lce6a, Lcn6, Muc15, Odam, Spag11a,
Spag11b, Spink13, Svs1, Tchhl1); and of these 17 genes,
5 genes (Bsph1, Defb42, Gm45826, Spag11a, and
Spag11b) were identified with human orthologs (BSPH1,
DEFB136, SPAG11A, and SPAG11B) that are also human
epididymis-specific (Fig. 6, Additional file 5: Table S5,
and Additional file 6: Table S6).
Specific to mouse testis and epididymis
Sixty-five genes were identified as reproductive tract-
specific in mouse with expression in both epididymis and
testis and/or testis cell. Of these 65 genes, 48 have human
orthologs; of these 48 genes, 24 are novel and not previ-
ously identified as male reproductive tract-specific; of these
24 genes, 14 have not been previously knocked out in the
mouse (1700009N14Rik, 4922502D21Rik, 4930563D23Rik,
D330045A20Rik, Defb28, Dgkk, Fam90a1b, Gm6871,
Hrasls5, Nxf3, Shc4, Spint3, Trpc5os, Wfdc9); and of these
14 genes, 3 genes (Spint3, Trpc5os, and Wfdc9) were identi-
fied with human orthologs (SPINT3, TRPC5OS, and
WFDC9) that are also human epididymis-specific (Fig. 6,
Additional file 5: Table S5, and Additional file 6: Table S6).
Functional validation of novel reproductive tract-specific
genes
Through the aforementioned studies, we identified
Spint3, Spint4, Ces5a, Pp2d1, and Saxo1 as congruent in
expression across both mouse and human datasets with
expression restricted to either the epididymis (Spint3,
Spint4, Ces5a) or the testis (Pp2d1 and Saxo1) (Figs. 3,
4, 5, and 6; Additional file 5: Table S5; Additional file 6:
Table S6). Spint5 was also identified as epididymis-
specific in mouse (Fig. 5, Additional file 6: Table S6);
however, in humans, SPINT5P is a pseudogene that is
not processed into protein. Conventional RT-PCR of a
panel of mouse and human tissue cDNAs confirmed epi-
didymis- or testis-restricted expression of Spint3, Spint4,
Ces5a, Pp2d1, and Saxo1 in both species and Spint5 in
mouse (Fig. 5).
To glean insight into the onset of expression for the
epididymis-specific genes, Spint3, Spint4, Spint5, and
Ces5a; whole epididymides from postnatal days (P) 3,
P6, P10, and P14; and epididymis segments (caput, cor-
pus, and cauda) from P21, P28, P35, and P60 aged mice
were collected and analyzed through RT-PCR
(Additional file 19: Fig. S10). Spint3 expression begins as
early as P3 (low) and gradually increases through P10
and P14 reaching steady levels throughout P21 to P60 in
all three segments of the epididymis (Additional file 19:
Fig. S10). In contrast, Spint4 and Spint5 display near
identical expression levels with no expression at P3, P6,
or P10, and expression apparent at P14 and later time
points, with expression restricted to corpus only at P21
and P28, and caput and corpus, but not cauda at P35
and P60 (Additional file 19: Fig. S10). RNAscope-based
fluorescence in situ hybridization revealed a distinct
segment-specific pattern of expression for Spint4 that
was identical to Spint5, with both showing expression in
most of the epithelial cells restricted to a brief region of
distal caput/proximal corpus (Additional file 20: Fig.
S11). Spint3, on the other hand, displayed a pattern of
expression in a majority of epithelial cells that begins
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just a bit further downstream along the corpus, but per-
sisting for much further along the corpus, throughout
the corpus and into the cauda (Additional file 20: Fig.
S11). These results indicate that Spint3 shares a role that
is distinct from Spint4 and Spint5 and indicates a poten-
tial redundancy between Spint4 and Spint5 and how
humans may have lost the evolutionary pressure to keep
SPINT5P as a protein-coding gene.
To glean insight into the potential spermatogenic cell
population(s) expressing Pp2d1 and Saxo1, we per-
formed RT-PCR of mouse testes isolated at postnatal
day (P) 3, a time point enriched for gonocytes; P6 (onset
of expression of type A spermatogonia); P10 (early sper-
matocytes); P14 (late spermatocytes); P21 (spermatids);
and P35 and P60, which display complete spermatogen-
esis [40] (Additional file 19: Fig. S10). Expression of
Pp2d1 and Saxo1 is detected at similar levels at P28 and
later, but not at P21 or before indicating expression dur-
ing spermiogenesis and spermiation (Additional file 19:
Fig. S10).
To determine the male reproductive requirement and
potential functional role of the identified novel male re-
productive tract-specific genes, Spint3, Ces5a, Pp2d1,
and Saxo1 were individually ablated by CRISPR/Cas9-
mediated zygote approach. Since in humans SPINT5P is
a pseudogene, and in mice, SPINT5 protein is most
similar in sequence to mouse SPINT4, we simultan-
eously ablated both mouse Spint4 and Spint5 genes,
which on mouse chromosome 2 are only separated by
12.9 kilobases. The efficiency of generating each mutant
is summarized in Additional file 1: Table S11. Each of
the genes contained deletions of differing sizes and gen-
omic targets. The genomic sequences flanking the dele-
tion in each mutant are presented in Additional file 1:
Table S12, and representative Sanger sequencing results
for each mutant are presented in Fig. 8. Using the for-
ward and reverse primer pairs presented in Fig. 8a–e
and listed in Additional file 1: Table S13, offspring carry-
ing the mutant alleles were identified through routine
genotyping (Fig. 8k–o).
Spint3, Spint4/5, Ces5a, Pp2d1, and Saxo1 knockout
mouse lines were examined in parallel with littermate
controls of equivalent age to determine the effect of gene
ablation on spermatogenesis, sperm maturation, and fer-
tility in male mice. None of the knockout strains gener-
ated in this study displayed any overtly abnormal
appearance, difference in body weight (Fig. 9) or com-
position, or difference in behavior when compared to
the controls.
To determine the male reproductive requirement of
each of the genes of interest, Spint3, Spint4/5, Ces5a,
Pp2d1, and Saxo1 knockout and control adult male mice
were housed continuously with two females for 3 months
and the size and number of litters were recorded.
Although Spint3, Pp2d1, and Saxo1 knockout males
sired a number and size of litters during the test mating
period that was not significantly different from controls
(Fig. 9a–c), Spint4/5 and Ces5a knockout males sired
significantly fewer litters and pups over the test mating
period (Fig. 9a–c). Spint4/5 null males displayed a statis-
tically significant 95% reduction in the number of litters
and pups sired per male and statistically significant 64%
reduction in litter size, over the 3-month mating period
(N = 9 controls, N = 9 KOs) (Fig. 9). Seven out of 9 males
displayed complete infertility, and the two remaining
males, who sired pups, sired pups at a significantly re-
duced number of litters and pups per month with litters
of reduced litter size (Fig. 9a–c). This fertility defect in
Spint4/5 double KO males was not associated with any
significant changes in epididymis and testis histology
(Additional file 21: Fig. S12) or sperm numbers, motility,
and morphology (Fig. 9g–i).
Ces5a null males displayed a variegated phenotype
with an overall statistically significant 50% reduction in
the number of litters and pups sired per male, but no sig-
nificant difference in litter size, over a 3-month mating
period (N = 9 controls, N = 9 KOs). The fertility defect in
Ces5a KO males was associated with significant changes
in epididymis histology (Additional file 22: Fig. S13) and
significant reductions in sperm motility and progressive
motility (Fig. 9h, i). Ces5a null males displayed a 50% re-
duction in sperm motility and progressive cells, a 50% in-
crease in static cells, and a 25% decrease in average path
velocity and progressive velocity after hyperactivation. No
changes in testis histology were found (Additional file 22:
Fig. S13), and despite the sperm motility defect, scanning
electron microscopy failed to identify a morphological
defect in Ces5a null sperm in comparison to controls
(Additional file 23: Fig. S14).
The epididymides and testes weights of Spint3, Spint4/5,
Ces5a, Pp2d1, and Saxo1 knockout mice were not signifi-
cantly different from littermate control mice (Fig. 9e, f).
Histological analyses of testes from Spint3, Spint4/5,
Ces5a, Pp2d1, and Saxo1 knockout mice revealed all had
seminiferous tubules with intact epithelia and the pres-
ence of all germ cell subtypes and all stages of spermato-
genesis (Additional file 21: Fig. S12 and Additional file 24:
Fig. S15). Histological analyses of caput, corpus, and cauda
from Spint3, Spint4/5, Pp2d1, and Saxo1 KO mice re-
vealed spermatozoa in tubule lumens of all knockouts
with no significant differences in epididymal histology in
comparison to controls (Additional file 21: Fig. S12 and
Additional file 24: Fig. S15). However, Ces5a knockout
mice displayed significant histological abnormalities in-
cluding lumen dilation (possibly from occlusion), inflam-
mation, and the appearance of abnormal epithelia
(Additional file 22: Fig. S13). Computer-assisted sperm
analysis of Spint3, Spint4/5, Pp2d1, and Saxo1 knockouts
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Fig. 8 Generation of knockout mice for functional validation. a–e Genomic structure and knockout strategy for mouse Spint3 (a), Spint4/5 (b),
Ces5a (c), Pp2d1 (d), and Saxo1 (e). Single or dual sgRNAs were designed to target the indicated exons in each gene. Each founder animal’s
deletion mutation is indicated with red hash lines. For all but Spint4/5, F1 and R1 are wild-type primers and F2 and R2 are mutant primers. For
Spint4/5, F1 of Spint4 was combined with R2 of Spint5 to detect the mutant allele. f–j Representative Sanger sequence result of mutant mice
depicted in a–e, respectively. k–o Representative genotype result of mutant mice using the indicated primers in a–e, respectively.
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Fig. 9 Phenotype analysis of CRISPR/Cas9 generated null mice for determining the contraceptive potential of the selected genes. Spint4/5 and
Ces5a null mice show significant fertility defects; meanwhile, Spint3, Pp2d1, and Saxo1 null mice appear normal. Fertility (a–c), body and
reproductive organ weights (d–f), and sperm parameters (g–i) were all measured between knockout (−/−) and littermate control [wild-type (+/+)
and heterozygous (+/−)] mice as indicated. Bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005. ns, not significant.
Robertson et al. BMC Biology          (2020) 18:103 Page 16 of 28
showed no statistically significant differences across all
measured parameters including sperm concentration,
sperm motility, and progressive motility (Fig. 9g–i). Ces5a
knockouts displayed significant decreases in sperm num-
ber and sperm motility (Fig. 9h, i); however, cauda epi-
didymal sperm isolated from a variety of Ces5a null
animals looked morphologically indistinguishable to con-
trols (Additional file 23: Fig. S14).
Discussion
To date, the etiology of idiopathic male infertility is not
fully understood, and hormonal male contraceptives have
not been effective. Therefore, identification of novel repro-
ductive tract-specific genes, and elucidating the functional
requirement or lack thereof of these genes, is essential to-
wards understanding the etiology of male infertility and
the development of male contraceptives. Despite signifi-
cant advances in our understanding of the human and ro-
dent testis and epididymis transcriptome, mostly through
microarray-based studies, no prior studies have utilized
purified human testis cells for the identification of human
testis-specific transcripts, no prior studies have utilized
the more state-of-the-art RNA-seq-based transcriptomics
methodology for analysis of human epididymis-specific
transcripts, and no prior studies have utilized RNA-seq
analysis of rodent reproductive tissues or cells to identify
rodent reproductive tract-specific transcripts. To address
these gaps in knowledge, and to increase the number of
identified reproductive tract-specific genes using the most
relevant high-throughput transcriptomics methodology,
we analyzed in parallel on a custom bioinformatics pipe-
line a large number of published and newly acquired hu-
man and mouse RNA-seq datasets. Through our studies,
we identified and verified many novel male reproductive
tract-specific transcripts in both species, and through the
CRISPR/Cas9 system, we interrogated the reproductive re-
quirement of a subset of these genes. We found that
Spint4 (together with Spint5) in mice is required for nor-
mal male mouse fertility, and although not required for
male fertility, we identified Ces5a as playing a major bio-
logical role in the epididymis. We report the remaining
genes that we knocked out—Spint3, Pp2d1, and Saxo1—
as dispensable for male reproductive function, which is es-
sential information to disseminate to the scientific com-
munity. Our study also verified the male reproductive
tract-specific expression of many previously identified
genes (Additional file 13: Fig. S5, Additional file 15:
Fig. S7), and genes for which previously published
mouse models display male infertility phenotypes
(Additional file 14: Fig. S6). This later group of
already functionally validated genes serves as potential
male contraceptive targets worth underscoring to the
research community.
Prior to massively parallel microarray-based and RNA-
seq-based transcriptomics analyses for the identification
of reproductive tract-specific genes, the NCBI UniGene
database was a valuable resource for many in the male re-
productive biology field for identifying testis-specific tran-
scripts [4, 41–43]. Although in our study we only
considered prior microarray-based and RNA-seq-based
studies when considering the novelty of the genes that we
identified, it is worth noting that several genes that we
identified—not previously identified in microarray-based
and RNA-seq-based transcriptomics studies—were previ-
ously identified through studies that solely utilized the
UniGene database [41, 42]. Nineteen human genes that
we identified—C16orf82, CCDC27, CPA5, FAM217A,
FAM46D, FAM47C, FBXO24, FBXW10, FKBP6, GALN
TL5, KCNU1, MAGEB3, MROH2B, NUTM1, PRDM9,
RBMXL3, SPATA31E1, TRIML1, and TRPC5OS—were
previously identified by Liu et al. [42], and seven mouse
genes that we identified—1700013D24Rik, Akap3,
Ankrd36, Hrasls5, Spesp1, Tex22, and Ubqlnl—were previ-
ously identified by Choi et al. [41] and Liu et al. [42].
Thus, our results confirm the findings of these previous
studies.
Since more than half of all human protein-coding
genes are categorized as unknown in terms of drug tar-
get potential (Additional file 11 - Table S8), and only
30% encode for classically druggable enzymes, GPCRs,
ion channels, nuclear receptors, and transporters (Add-
itional file 10 - Fig. S4), the potential to find new undis-
covered drug targets that can be drugged using classical
approaches is somewhat limited. Indeed, in our study,
we found one hundred and nine genes to be novel in
terms of previously published high-throughput tran-
scriptomics studies, without a current reported mouse
model, and reproductive tract-specific in both humans
and mice (Figs. 2, 3, and 6). Many of these genes (93
genes; 85%) fall into the category of unknown and may
otherwise be considered “undruggable” due to various
challenges with existing targeting approaches [10]. How-
ever, the contraceptive potential of these genes should
not be overseen, but rather investigated for potential
identification of a high-affinity small molecule that can
either interfere with protein-protein interaction (PPI) or
target the protein specifically for degradation using a
new technology called Proteolysis Targeting Chimeras
(PROTACs). Protein-protein interaction targets are not
deemed undruggable, based on the discovery of small
molecules capable of deeper and higher affinity binding
within the contact surfaces of the target protein [44].
Additionally, once a high-affinity small molecule against
a specific target protein is identified, an engineered
PROTAC molecule can mark a target protein for protea-
somal degradation by linking the target protein to the
polypeptide co-factor, ubiquitin [45–47]. There are
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currently various combinations of PROTACs developed
to overcome the limitations of cell permeability, stability,
solubility, selectivity, and tissue distribution [48–51].
Therefore, disrupting PPIs or utilizing PROTACs pro-
vides the potential to greatly promote the development
of contraceptive drugs against the “undruggable” non-
enzymatic target protein space.
Drug target specificity of novel targets
If gene knockouts for closely related and ubiquitously
expressed paralogs display no abnormal phenotype, then
unintended drug targeting of these proteins may result
in no side effects in humans. However, the burden of
safety for a male contraceptive is extremely high, and if
it can be avoided, targeting non-reproductive tract-
expressed proteins in humans should be avoided since
the functional requirements for these proteins may not
be fully understood. Further, although mice are one of
the best models for human disease, they are unable to
communicate when they are unwell, a phenomenon that
may occur independent of any measurable phenotypic
traits. Thus, potential reported side effects in humans
during clinical trials may have been present, but missed,
during animal studies, or in fact be present in humans
and not in mice because of the vast biological differences
across these two species. Thus, with drug safety in mind,
reproductive tract-specific candidates should be priori-
tized based on somatic cell-expressed protein sequence
similarity, especially in the drug binding pocket.
According to Ensembl, several novel reproductive
tract-specific genes without mouse models that we iden-
tified and verified—AC022167.5, AL672043.1, BHMG1,
C1orf105, C2orf92, C4orf51, CCDC196, SPINT3, TEX44,
TEX48, TEX51, and TRPC5OS (Figs. 3, 4, and 5;
Additional file 5: Table S5)—have no known associated
paralogs, indicating reproductive tract-specific drug tar-
geting is highly likely. Additionally, SPAG11A and
SPAG11B are epididymis-specific paralogs (Figs. 3, 4,
and 5; Additional file 5: Table S5) with no other known
paralogs according to Ensembl. EFCAB5 (Figs. 3 and 5,
Additional file 5: Table S5) has a ubiquitously expressed
paralog, NSRP1, with only 7% amino acid sequence simi-
larity, indicating specific drug targeting potential for this
candidate. Likewise, ERICH6 and MROH2B (Figs. 3 and 5,
Additional file 5: Table S5) have ubiquitously expressed
paralogs ERICH6B and MROH2A, respectively, with 20%
and 30% amino acid sequence similarity, indicating rea-
sonable potential for specific drug targeting.
PRR23A, PRR23B, and PRR23C are testis-specific para-
logs (Figs. 3 and 5, Additional file 5: Table S5) with
PRR23D2 as the next closest paralog according to
Ensembl. Since PRR23D2 has less than 26% amino acid
sequence similarity to PRR23A, PRR23B, and PRR23C,
but appears to be epididymis-specific according to the
Human Protein Atlas [52], all four proteins of unknown
function make suitable drug candidates. Likewise, SPAT
A31D1, SPATA31D3, and SPATA31D4 are testis-specific
paralogs (Figs. 3 and 5, Additional file 5: Table S5) with
SPATA31A5 as the next closest paralog according to
Ensembl. Since SPATA31A5 has less than 26% sequence
similarity to SPATA31D1, SPATA31D3, and SPAT
A31D4, but also appears to be reproductive tract-
specific according to HPA [52], all four proteins with
unknown function also appear to be worthy of consider-
ation for potential drug targeting. TPTE and TPTE2 are
testis-specific paralogs (Figs. 3 and 5, Additional file 5:
Table S5) with ubiquitously expressed PTEN as the next
closest paralog according to Ensembl. Since PTEN has
less than 25% sequence similarity to TPTE and TPTE2,
off-target effects appear to be unlikely. Likewise,
WFDC10A, WFDC10B, and WFDC13 are all
epididymis-specific paralogs with the closest non-
reproductive tract-expressed paralog, WFDC5, having
less than 26% sequence similarity to any of the RTS
paralogs, also indicating high drug specificity potential.
Several additional novel reproductive tract-specific en-
zyme and GPCR genes without mouse models that we
identified—GPR156, PRSS38, PRSS48, SULT6B1, TMPR
SS7, TRIML2, and TTLL8 (Fig. 3, 4, and 5; Additional file 5:
Table S5)—have non-reproductive tract-expressed para-
logs with less than 35% sequence similarity indicating
good drug specificity potential. A novel testis-specific
transporter gene without a reported mouse model that we
identified, SLC25A52, would make a poor drug candidate
since its closest paralog, SLC25A51, is 93% similar in
amino acid sequence and ubiquitously expressed. CPA5,
IQCA1L, and PPP4R3C have ubiquitously expressed para-
logs, CPA1, IQCA1, and PPP4R3B, respectively, with 50–
60% protein sequence similarity indicating careful consid-
eration must be made for potential drug targeting without
off-target effects.
Of the seventy-three genes that our study identifies as
reproductive tract-specific in humans and for which a
published mouse model shows male infertility phenotype
(Additional file 14: Fig. S6) [28, 29, 31], it is worth not-
ing that 21 genes—CNBD2, DEFB110, FAM170A,
FBXO47, MEIG1, MEIOB, MEIOC, ODF1, ODF4,
REC114, RNF17, SPACA1, SPATA22, SPEM1, SPO11,
SYCP1, TERB1, TEX19, TEX38, TNP2, and TOPAZ—do
not have any associated paralogs and, thereby, may be
considered most suitable for further drug development.
However, it is also worth noting that it may be possible
that genes required for male fertility in mice may not ne-
cessarily be required for male fertility in humans. Of the
seventy-three human reproductive tract-specific genes
our study identified with male mouse infertility pheno-
types, twenty-seven genes—ACTL7B [53], AKAP4 [54],
BOLL [55], BRDT [55–60], CATSPER4 [54], CCDC155
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[61], FKBP6 [55, 61–63], MEIG1 [64], MEIOB [55–57,
65], NANOS2 [55, 61], ODF1 [55], PRDM9 [61, 66, 67],
PRSS37 [55], RAD21L1 [68], RBMXL2 [55, 62], RNF17
[69], SOHLH2 [61, 70], SPACA1 [55], SPATA16 [55, 56],
SPEM1 [55], SPO11 [55, 58, 61], SUN5 [55–57], SYCP1
[55], TEX38 [55], TNP2 [55], TSSK1B [62], and ZPBP
[55]—are currently associated with mutations underlying
human male infertility, confirming a similar functional
requirement for these genes in humans may exist. For
the remaining 45 genes, however, either these genes are
not required for human male fertility as they are re-
quired in mice, or associated mutations in male infertile
patients have not yet been reported.
Although many reproductive tract-specific genes have
been studied through functional genetics approaches,
many remain to be solved. Elucidating the function of
these novel genes is necessary to build a better under-
standing of the factors underlying spermatogenesis and
sperm maturation, which has implications in under-
standing the etiology of male infertility and the develop-
ment of male contraceptives. In this study, four
epididymis-specific genes (Spint3, Spint4, Spint5, and
Ces5a) and two testis-specific genes (Pp2d1 and Saxo1)
were deleted in mice to determine their functional re-
quirement in male fertility and potential utility as male
contraceptive target. We chose to study these genes be-
cause all but Saxo1 encode enzymes or enzyme-related
protein products and are thus considered druggable in
the classical sense. Saxo1, a cilia-related gene, was
chosen because prior literature demonstrated expression
in sperm [71]. Although not druggable in the classical
sense, if targeted through non-canonical approaches,
one could obtain a fast-acting drug with greater revers-
ibility potential and a decreased likelihood of affecting
testicular function and size. The epididymis-specific
genes we chose to target for functional analysis, by the
very nature of their tissue’s expression, also fit this po-
tential drug profile of modulating only the latest stages
of sperm development.
Analyses of testis and epididymis organ weights and
histology, sperm parameters and morphology, and fertil-
ity revealed no significant differences in Spint3, Pp2d1,
and Saxo1 knockout mice in comparison to littermate
controls demonstrating that, individually, Spint3, Pp2d1,
and Saxo1 are not required for male mouse fertility and
are not suitable targets for the development of a male
contraceptive. However, we found partial effects on male
fertility in Ces5a knockout mice and profound effects on
male fertility in Spint4/5 double knockout mice.
CES5A is a member of a multigene family of mamma-
lian carboxylesterases that can hydrolyze ester, thioester,
amide, and carbamate linkages in a wide variety of en-
dogenous and exogenous molecular substrates, including
triglycerides, thus playing key roles in both metabolism
and detoxification [72–75]. CES5A shares roughly simi-
lar percent homology (~ 40% homology) to all four of its
related paralogs, CES1, CES2, CES3, and CES4A. Human
carboxylesterase 1 (CES1) is predominantly expressed in
the liver and has been shown to have triglyceride hydro-
lase activity as overexpression of human CES1 in cells
leads to an increase in cholesteryl ester hydrolysis and
free cholesterol efflux [76]. Further, mouse CES1G—a
protein expressed by one of a cluster of eight syntenic
genes (Ces1a through Ces1h) orthologous to the human
CES1 gene—has been shown to have triglyceride hydro-
lase activity as Ces1g null mice display hyperlipidemia
and abnormal lipid homeostasis including increased liver
and circulating cholesterol and triglycerides, and altered
saturated and unsaturated fatty acid levels [77, 78].
Therefore, it is likely that CES5A exhibits similar car-
boxylesterase activity in the epididymis hydrolyzing cho-
lesteryl ester and affecting free cholesterol efflux. Indeed,
recombinant CES5A protein has been previously shown
to have carboxylesterase activity hydrolyzing cholesterol
ester and choline ester [79]. Since sperm cholesterol
content is significantly decreased during epididymal
maturation [80, 81] and a proper cholesterol/phospho-
lipid (C/PL) ratio of the sperm plasma membrane is re-
quired for sperm capacitation [82, 83], CES5A may be
pivotal in regulating sperm membrane cholesterol and
lipid levels to ensure the normal function of male gam-
etes in the last steps of the fertilization process.
The most closely related paralog to SPINT4 is EPPIN,
which, as reviewed in O’Rand et al., has at least three
physiological functions [16]. EPPIN inhibits sperm motil-
ity when it binds the semen coagulation protein Semeno-
gelin 1 (SEMG1) on the sperm surface [84]; it modulates
the proteolytic activity of prostate-specific antigen (PSA),
a serine protease, against its seminal plasma substrate,
SEMG1 [85]; and it exhibits strong antibacterial activity
[86]. These functions are postulated to prevent premature
hyperactivation and capacitation of sperm in the fe-
male reproductive tract [16], and to protect spermato-
zoa from proteolytic and bacterial attack during
transit in the female reproductive tract [11, 16]. Thus,
it is possible that the physiological function of SPIN
T4 is similar. However, unlike SPINT1 and SPINT2,
which have been shown to act as protease inhibitors
against a wide variety of PRSS and TMPRSS proteases
[87–90], when tested against a panel of eight prote-
ases (including PSA, trypsin, chymotrypsin, plasmin,
urokinase, thrombin, Factor Xa, and elastase), SPINT3
and SPINT4 were shown to lack protease inhibiting
capability [91]. This indicates that either the protease
inhibiting properties of SPINT3 and SPINT4 were lost
in favor of yet unknown functions or their protease
activity has a narrower spectrum of inhibition against
unknown targets.
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Since Spint4/5 null male mice are severely subfertile,
without an apparent difference in epididymis histology,
sperm number, sperm morphology, and sperm motility
parameters in comparison to the wild-type (WT) mice,
this phenocopies the reproductive phenotype of several
null mice of testis-, epididymis-, or prostate-specific
genes (Sof1, Tmem95, and Spaca6; Pate8, and Pate10),
which reveal a requirement in regulating sperm migra-
tion through the oviduct and sperm-oocyte fusion in
mice [92, 93]. A severe fertility defect associated with
normal sperm number, morphology, and motility is also
shared among mice lacking the sperm membrane pro-
tein ADAM3, thought to be crucial in sperm-ZP binding
and sperm migration through the uterotubular junction
(UTJ) [94, 95]. More than 10 proteins including 2 prote-
ases (ACE, ADAM1A, ADAM2, CALR3, CLGN,
CMTM2A/B, PDILT, PMIS2, PRSS37, RNASE10,
TEX101, and TPST2) have been described that affect the
processing and/or localization of ADAM3 protein in
spermatozoa [96, 97]. Further studies with Spint4/5 null
mice are required to determine whether sperm behavior
in the female reproductive tract, specifically the sperm
migration through the UTJ, is adversely affected. Since a
large 16,797-bp genomic region—including the inter-
genic region between the Spint4 and Spint5 genes—was
deleted (Fig. 8; Additional file 1: Table S12), based on
the evidence presented in this manuscript, we cannot ex-
clude the possibility that cis-acting elements and/or
trans-acting factors affecting the expression of other
genes may have contributed to the phenotype of these
mice.
Lack of protein-coding ability of human SPINT5P does
not necessarily indicate that this pseudogene is function-
ally obsolete. Pseudogenes have been shown to play roles
in gene expression and gene regulation [98]. For ex-
ample, pseudogene transcripts can act as competitive en-
dogenous RNAs (ceRNA) through competitive binding
of miRNA, which results in regulation of gene expres-
sion [99]. To this end, studying the functional require-
ment of Spint5 in male mice is necessary to further our
knowledge of evolutionarily conserved genes between
species.
Since humans are genetically diverse, a limitation to
phenotype characterization of genetically manipulated
mice is the reliance of a single mouse background to the
examination of complex genetic outcomes, such as fertil-
ity, that is under the control of many genes with differ-
ent levels of contribution to the phenotype [100]. It is
possible that a gene that causes complete infertility in an
inbred mouse background may only cause partial infer-
tility or subfertility in a different inbred line or more ro-
bust outbred background. Since the mice used in our
study were a cross between C57BL/6 (B6) mice and
DBA/2 (D2) mice, and thus, these B6D2F1 mice are
heterozygous for B6 and D2 alleles at all loci in their
genome, we can eliminate infertility susceptibility of ei-
ther the B6 or the D2 background as the cause for fertil-
ity defects in Ces5a and Spint4/5 mice. It does remain to
be determined, however, whether the phenotype of the
genes we knocked out would be more or less severe on a
different mouse background, and if required for male
fertility in humans, the level of contribution to male fer-
tility of these genes across genetically diverse men.
A limitation to this study is the reliance on mRNA
abundance positively correlating with protein abun-
dance. Future studies are necessary to elucidate the rela-
tionship between mRNA and protein expression levels
of the candidate genes identified in our study. Further-
more, despite batch corrections that were made, tech-
nical differences in sample preparation and integrity
across the various published RNA-seq datasets can influ-
ence the results of our findings. One of the major advan-
tages to our study design is the use of RNA-seq datasets
from purified human and mouse germ cells and Sertoli
cells to identify reproductive tract-specific targets since
the use of whole testes for the identification of cell type-
specific transcripts in past studies is subject to dilution
effects. However, this advantage could also be consid-
ered a disadvantage since purified cells from non-
reproductive tissues were not used for comparison but,
if analyzed, purified cells from non-reproductive tis-
sues may have revealed significant levels of expression
in non-reproductive tissues. Ultimately, functional stud-
ies in animals and humans will help to confirm whether
genes identified in our study are essential for male fertil-
ity and not any other physiological process.
Conclusions
Through the integration of hundreds of published and
newly acquired human and mouse reproductive and
non-reproductive tissue and cell RNA-seq datasets, we
have generated a list of novel genes expressed predomin-
antly or exclusively in the male reproductive tract that
are worthy of consideration for functional validation in
an animal model and potential targeting for a male
contraceptive. Our results further validate a functional
requirement for Spint4/5 and Ces5a in male mouse fer-
tility, while demonstrating that Spint3, Pp2d1, and Saxo1
are each individually dispensable for male mouse fertil-
ity. Identifying novel reproductive tract-specific genes
congruent across species adds insight into organismal
biology and valuable information that can be used to
identify potential male contraceptive drug target candi-
dates. Furthermore, elucidating the individual functional
requirement or lack thereof of these novel genes builds a
better understanding of the factors underlying spermato-
genesis and sperm maturation, which has implications in
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understanding the etiology of male infertility and further
validation of the utility of a potential male contraceptive
target.
Materials and methods
Human tissues and RNAs
The de novo isolated human testes and epididymides in-
cluded in this study were obtained from three donors
through a local organ transplant program in Quebec,
Canada, called Transplant Quebec. All procedures were
approved by the local ethics committee, and written
consent was obtained from each respective donor’s fam-
ily. The donors were of 40, 52, and 65 years of age with
no preexisting medical condition that could affect repro-
ductive function. Donor testes and epididymides were
removed under artificial circulation to preserve other or-
gans that were assigned for transplantation. Each testis
and epididymis were dissected in the laboratory of Rob-
ert Sullivan at Université Laval. Each epididymis was dis-
sected into three segments corresponding to the caput,
corpus, and cauda regions and minced into small tissue
pieces. Testes and epididymides tissue fragments were
immediately snap frozen in liquid nitrogen, stored at −
80 °C, and shipped frozen to Baylor College of Medicine
for further processing. Eight non-reproductive tissue
types (kidney, liver, lung, skin, spleen, and stomach) and
2 female reproductive tissues (ovary and uterus) were
obtained from the Baylor College of Medicine Tissue
Acquisition and Pathology Core. Thirteen non-
reproductive tissue types (adipose, adrenal gland, brain,
colon, heart, leukocytes, pancreas, prostate, salivary
gland, skeletal muscle, small intestine, smooth muscle,
thyroid) were obtained as purified RNAs from Takara
Bio (Kusatsu, Japan). Human testes and epididymis seg-
ments were used for de novo RNA-seq analysis; all hu-
man tissues and/or resulting RNAs were used for RT-
PCR verification.
Mouse tissues and RNAs
Mouse tissues [testis, caput, corpus, cauda, ovary, uterus,
and 17 non-reproductive tissue types (adipose, bladder,
brain, colon, eye, heart, kidney, liver, lung, prostate, skel-
etal muscle, skin, small intestine, spleen, stomach)] were
obtained from dissection of B6/129 mice; the remaining
2 non-reproductive tissues (smooth muscle and thyroid)
were obtained as purified RNAs from Takara Bio. Mouse
epididymis segments were used for de novo RNA-seq
analysis; all mouse tissues and/or resulting RNAs were
used for RT-PCR verification.
RNA isolation and reverse-transcription PCR
RNA for both RNA-seq and/or RT-PCR verification was
isolated from human and mouse tissues using TRIzol/
chloroform extraction method followed by RNeasy Mini
kit from Qiagen with on-column DNase (Qiagen) treat-
ment using the manufacturer’s protocol. RNAs used for
RNA-seq were assessed by Bioanalyzer for RNA integ-
rity. For RT-PCR, RNA was reverse-transcribed to
cDNA using SuperScript III Reverse Transcriptase from
Thermo Fisher according to the manufacturer’s protocol.
cDNA was then PCR amplified using gene-specific
primers designed using NCBI primer design tool. Primer
sequences are listed in Additional file 1: Table S14.
Library generation for RNA-seq
RNA-seq libraries were made using KAPA stranded
mRNA-seq kit (KK8420). Briefly, Poly-A RNA was puri-
fied from total RNA using Oligo-dT beads; subsequently,
it was fragmented to small size; and first strand cDNA
was synthesized. Second strand cDNA was synthesized
and marked with dUTP. Resultant cDNA was used for
end repair, A-tailing, and adaptor ligation. Finally, the li-
brary was amplified for sequencing on an Illumina
NovaSeq 6000 platform. The strand marked with dUTP
was not amplified, allowing strand-specific sequencing.
Sequence alignment, quantification, and differential gene
expression
Human testes, human epididymis segments, and mouse
epididymis segments were sequenced by the Department
of Molecular and Human Genetics Functional Genomics
Core at Baylor College of Medicine (Additional file 1:
Table S1 and Additional file 1: Table S2). Previously
published reproductive and non-reproductive tissue and
cell sequences were downloaded from the Sequence
Read Archive (SRA) [101] (Additional file 1: Table S1
and Additional file 1: Table S2). All sequences were
trimmed using Trim Galore! and aligned against the hu-
man genome (GRCh38) or mouse genome (GRCm38)
using HISAT2 [102, 103]. Gene expression in each tissue
was quantified using featureCounts, filtered for only
protein-coding genes, and batch corrected by removing
unwanted variation using the RUVr method from RUV-
seq [104, 105]. Differential gene expression was deter-
mined for each reproductive tissue against each non-
reproductive tissue using the R package EdgeR [106].
Principal component analysis
Principal component analysis (PCA) was performed in
the R statistical environment using the log2 counts per
million (CPM) for each gene in the corresponding tissue
after using the RUVr method to correct for batch vari-
ation as described above.
Identification of male reproductive-specific gene drug
candidates
Our procedure for identifying a reproductive-specific
gene was repeated for each reproductive tissue or cell
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sample independently. The following selection criteria
were applied to each reproductive tissue or cell sample.
First, the non-reproductive tissue with the maximum ex-
pression, expressed as the log2 fold change between the
non-reproductive tissue and the reproductive tissue or
cell of interest, was identified for each gene using the re-
sults from the differential gene expression analysis. Sec-
ond, we identified reproductive-specific gene drug
candidates using three filters: a false discovery rate
(FDR) filter, a maximum transcript per million (TPM)
expression value filter on the non-reproductive sample
with the maximum expression identified as described
above, and a minimum TPM expression value filter on
the reproductive tissue or cell sample of interest. A gene
was kept if the FDR from the differential gene expression
analysis was less than or equal to 0.05 for the compari-
son of the reproductive tissue or cell sample of interest
to the non-reproductive tissue with the maximum ex-
pression. A gene was considered to be a male reproduct-
ive tissue-specific drug target if the average TPM
expression value in the non-reproductive tissue with the
maximum expression from the differential analysis was
less than or equal to 1.0 for human (2.0 for mice), and if
the average TPM expression value for that gene was
greater than or equal to 10.0 for human (8.0 for mice) in
the reproductive tissue or cell sample of interest. The
average and standard deviation of the TPM expression
value for each gene was calculated from the RUVr batch
corrected counts per million expression value for each
tissue or cell sample.
Human to mouse gene symbol conversion
We consolidated data from Ensembl BioMart [29] and
Mouse Genome Informatics (MGI) [28] to create a com-
prehensive database of mouse gene symbols orthologous
to human genes and vice versa. Each respective species’
stable ensemble gene ID was used for each conversion,
with gene symbol as the final output.
Previously identified genes
As mentioned, several notable high-throughput gene ex-
pression studies using microarrays or RNA-seq, focused
on identifying male reproductive tract-specific genes,
have been previously published [2, 4–9]. Tables and
Supplementary Tables from these studies were gathered
to collect the lists of genes previously identified. For
microarray-based studies, Affymetrix IDs were used to
confirm the identity of a listed gene, based on current
sequence mappings, or in many cases to identify de novo
the identity of a gene only known at the time of the
study by its Affymetrix ID and not gene symbol. For
mouse and rat studies, gene symbols were converted to
orthologous human symbols, to systematically catalog
both the rodent and corresponding human symbols as
previously identified. For example, 399 Affymetrix probe
IDs were listed as reproductive tract-specific in Johnston
et al. [8]. After re-identification of gene symbols based
on current Ensembl sequence mappings, 42 identified
gene symbols remained the same, 160 received an up-
dated/replacement gene symbol identification, 103 genes
that were previously unidentified received a new gene
symbol identification, 26 Affymetrix IDs lost mapping to
any gene symbol, and 67 remain unidentified. Out of the
total of 305 Affymetrix IDs that mapped to 301 current
rat gene symbols, 257 rat gene symbols converted to at
least one human ortholog gene symbol that was either
the same symbol or different. Both rat and human sym-
bols, based on new mappings, were considered previ-
ously identified. For the complete list of previously
identified genes, see Additional file 18: Table S10.
Drug target type classification
Genes were classified as encoding either enzymes,
epigenetic-related proteins, G protein-coupled receptors
(GPCRs), ion channels, kinases, nuclear receptors, or-
phan GPCRs (oGPCRs), transcription factors, trans-
porters, or unknown proteins based on data obtained
from Illuminating the Druggable Genome [27]
(Additional file 11: Table S8).
Availability of a mouse model
We used data obtained from Ensembl BioMart [29],
MGI [28], the International Mouse Phenotyping Consor-
tium (IMPC) [31], and PubMed searches to generate a
comprehensive database identifying the existence of a
mouse model for all mouse genes (Additional file 12:
Table S9). We then queried our identified candidate hu-
man and mouse genes against this list. For a given hu-
man gene, we queried the equivalent mouse ortholog
gene symbol(s).
Experimental animals
Spint3, Spint4/5, Ces5a, Pp2d1, and Saxo1 knockout
mice were produced at Baylor College of Medicine.
B6D2F1 (C57BL/6 × DBA2) mice were used as embryo
donors, and CD1 mice were used as foster mothers.
Mice were purchased from Charles River (Wilmington,
MA). All mice were housed in a temperature-controlled
environment with 12-h light cycles and free access to
food and water. Mice were housed in accordance with
NIH guidelines, and all animal experiments were ap-
proved by the Institutional Animal Care and Use Com-
mittee (IACUC) at Baylor College of Medicine.
Generation of Spint3, Spint4/5, Ces5a, Pp2d1, and Saxo1
knockout mice
To generate Spint3, Spint4/5, Ces5a, Pp2d1, and Saxo1
knockout mice, gRNA/Cas9 ribonucleoprotein complex
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was electroporated into fertilized eggs and transplanted
into surrogate mothers as previously described [107].
Briefly, to harvest fertilized eggs, CARD HyperOva (0.1
mL, Cosmo Bio) was injected into the abdominal cavity
of B6D2F1 females (Charles River), followed by human
chorionic gonadotropin (hCG) (5 units, EMD Chemi-
cals). Forty-eight hours after CARD HyperOva, B6D2F1
males were allowed to mate naturally. Twenty hours
after mating, fertilized eggs with 2 pronuclei were col-
lected for electroporation. Custom crRNAs targeting
each gene were purchased from Millipore-Sigma. The
sequences for all guide RNAs used for CRISPR/Cas9-
mediated gene editing are listed in Additional file 1:
Table S11. crRNA and tracrRNA (Millipore-Sigma) were
diluted with nuclease-free water. The mixture was dena-
tured at 95 °C for 5 min and allowed to anneal by cool-
ing gradually to room temperature (1 h). Each gRNA
was mixed with Cas9 protein solution (Thermo Fisher
Scientific) and opti-MEM media (Thermo Fisher Scien-
tific), and then incubated at 37 °C for 5 min to prepare
the gRNA/Cas9 RNPs [final concentration, 300 ng/μL
Cas9 for 250 ng/μL of each gRNA]. The gRNA/Cas9
RNP solution was placed between electrodes with a 1-
mm gap in the ECM 830 Electroporation System (BTX).
Fertilized eggs were arranged between the electrodes,
and then, the electroporation was performed with the
following conditions: 30 V, 1-ms pulse duration, and 2
pulses separated by 100-ms pulse interval. For egg trans-
fer, electroporated embryos were transplanted into the
oviduct of pseudo-pregnant ICR recipients. After 19
days, offspring were obtained by natural birth or
Cesarean section. The F0 mice with sequence-predicted
heterozygous mutations were used for the mating with
additional B6D2F1 mice to generate homozygous mu-
tants. The F2 or later generations were used for the
phenotypic analyses.
Genotype analysis of knockout mice
For Sanger sequence analysis of mutant mice, genomic
DNA was isolated by incubating tail tips in lysis buffer
[20 mM Tris-HCl (pH 8.0), 5 mM EDTA, 400 mM NaCl,
0.3% SDS, and 200 μg/mL Actinase E solution] at 60 °C
overnight. Polymerase chain reactions (PCRs) amplifying
the genomic region containing the insertion/deletion
events were performed using KOD Xtreme enzyme
(TOYOBO, Osaka, Japan); PCR products were purified
using the QIAquick PCR Purification Kit (Qiagen, Carls-
bad, CA, USA) and sent for Sanger sequencing on an
ABI 3130XL Genetic Analyzer (Thermo Fisher Scientific,
Waltham, MA, USA) using the forward primer. For rou-
tine genotyping of mutant mice, genomic DNA was iso-
lated by separately incubating ear snips and tail tips in
50mM NaOH solution at 95 °C overnight and inactivat-
ing with 1M Tris pH = 8.0. PCRs amplifying wild-type
and mutant-specific amplicons were performed using 2X
amfiSure PCR Master Mix (GenDEPOT, Barker, TX). Pri-
mer sequences are listed in Additional file 1: Table S13.
Male fertility analysis
Upon sexual maturation (6–7 weeks of age), knockout
and littermate control male mice (n = 6–9 mice per
genotype) were continuously housed with two 7–8-
week-old wild-type B6D2F1/J female mice per male for
12 weeks. During the fertility test, the number of pups
was counted shortly after birth. The total number of lit-
ters and pups per male over the mating trial was calcu-
lated and divided by the number of months to generate
averages and statistics per genotype. The average num-
ber of pups per litter is based on the average litter size
per male where a litter is considered one or more pups.
Testis weights and testis and epididymis histology of
male mice
Knockout and littermate control male mice (n = 5–13
mice per genotype) that were 12 weeks of age were used
to examine body and reproductive organ weights, and
testicular and epididymal histology. Testes and epididy-
mides were fixed in Bouin’s fixative, embedded in paraf-
fin, sectioned at 5 μm thickness, and stained with 1%
periodic acid-Schiff (PAS) stain followed by counter-
staining with hematoxylin 2 solution. Histological images
were acquired with an Aperio AT2 slide scanner (Leica
Microsystems).
Sperm analysis
Knockout and littermate control male mice (n = 5–13
mice per genotype) that were 12 weeks of age were used
to examine sperm numbers and motility parameters
using computer-assisted sperm analysis (CASA). Cauda
of both epididymides was isolated, transferred into Hu-
man Tubule Fluid (HTF) (Irvine Scientific, Santa Ana,
CA) containing 5 mg/mL of BSA, minced, and placed in
a humidified incubator for 15 min at 37 °C with 5% CO2.
Following incubation, the sperm were diluted 1:50 in
HTF, added to a pre-warmed slide, and analyzed using a
Hamilton-Thorne Bioscience’s Ceros II instrument. Sev-
eral fields of view were illuminated and captured until at
least 200 cells were counted.
RNA in situ hybridization
RNAscope 2.5 HD Reagent Kit (RED) (cat. 322350, Ad-
vanced Cell Diagnostics, Newark, CA, USA) was used to
detect Spint3, Spint4, and Spint5 mRNA transcripts on
PFA-fixed, paraffin-embedded sections from 3-month-
old wild-type epididymis. The probes against Mm-
Spint3, Mm-Spint4, and Mm-Spint5 were custom-made,
and the standard positive control (Mm-Ppib, cat.
313911) and negative control (DapB, cat. 310043) probes
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were used. The assay was performed according to the
manufacturer’s instructions. Slides were counterstained
using DAPI and mounted using ProLong Glass Antifade
Mountant (Thermo Fisher Scientific Inc.). Multi-channel
fluorescent images were acquired with an Aperio VERSA
(Leica Microsystems).
Statistical analysis
All measurements are expressed as mean ± standard
error of the mean. Statistical differences were deter-
mined using Student’s t test. Differences were consid-
ered statistically significant if the P value was less than
0.05.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12915-020-00826-z.
Additional file 1: Tables S1, S2, S11, S12, S13, and S14. Table S1.
Summary of Human RNA-seq datasets. This table contains the SRA value
for each previously published human RNA-seq dataset that was
reanalyzed as part of this study. The GEO accession number for each new
human RNA-seq dataset generated and subsequently analyzed in this
study is also included. Table S2. Summary of Mouse RNA-seq datasets.
This table contains the SRA value for each previously published mouse
RNA-seq dataset that was reanalyzed as part of this study. The GEO
accession number for each new mouse sample generated and subse-
quently analyzed in this study is also included. Table S11. Single-guide
RNAs targeting the genes’ upstream (U) and downstream (D) regions
used for generating knockout mice. Efficiency of embryo transplantation
was presented using the number of total pups delivered by pseudopregnant
mice divided by the number of total embryos used for oviduct transplantation
(Total pups/embryos transplanted). Efficiency of genome editing was
determined by the number of pups carrying enzymatic mutations divided by
the number of pups subjected to genotyping (GM pups/pups genotyped).
Table S12. Sanger sequencing of detailed genotype of mutant DNA
sequences in all the five mouse lines. Table S13. Primers and PCR conditions
used for genotyping the mutant alleles of the knockout mouse lines. Table
S14. Human and mouse RT-PCR primer sequences used for verification of
reproductive tract-specificity.
Additional file 2: Fig. S1. Genes that passed the TPM and FDR filters in
at least one of the measured reproductive tissues or cells were visualized
using a heatmap of the RUVr batch corrected log2 CPM gene expression
values for the human (A) and mouse (B) samples.
Additional file 3: Table S3. Human Expression Summary. Contains
differential fold change, identity of the non-reproductive tissue with
maximal gene expression based on the differential gene analysis, false
detection rate (FDR) value, average and standard deviation TPM
expression values, and log2 CPM gene expression value for the human
samples. All protein-coding genes (18,305 genes) that had expression in
at least one reproductive tissue or cell is listed.
Additional file 4: Table S4. Mouse Expression Summary. Contains
differential fold change, identity of the non-reproductive tissue with
maximal gene expression based on the differential gene analysis, false
detection rate (FDR) value, average and standard deviation TPM expres-
sion values, and log2 CPM gene expression value for the mouse samples.
All protein-coding genes (16,891 genes) that had expression in at least
one reproductive tissue or cell is listed.
Additional file 5: Table S5. All human male reproductive tract-specific
genes that met the criteria of identification as reproductive tract-specific
in at least one male reproductive tissue or purified cell type, with the
level of fold change listed under the tissue or cell if all criteria were met.
The criteria of selection are as follows: FDR < 0.05; TPMrepro > 10; TPMnon--
repro, max < 1. A fold change value of 0 indicates the criteria were not
met for that that tissue or cell. Additional columns indicating 1.) the
equivalent mouse ortholog gene symbols (single or multiple symbols)
that exist, and 2.) if our studies identified any of these mouse orthologs
as reproductive tract-specific in mouse, are included.
Additional file 6: Table S6. All mouse male reproductive tract-specific
genes that met the criteria of identification as reproductive tract-specific
in at least one male reproductive tissue or purified cell type, with the
level of fold change listed under the tissue or cell if all criteria were met.
The criteria of selection are as follows: FDR < 0.05; TPMrepro > 8; TPMnon-re-
pro, max < 2. A fold change value of 0 indicates the criteria were not met
for that that tissue or cell. Additional columns indicating 1.) the equiva-
lent human ortholog gene symbols (single or multiple symbols) that
exist, and 2.) if our studies identified any of these human orthologs as re-
productive tract-specific in human, are included.
Additional file 7: Fig. S2. Summary of number of statistically significant
up and down-regulated genes, and quantification of candidate genes
with respect to the individual reproductive tissue or cell of interest. The
plots in panels (A) and (B) summarizes the number of statistically signifi-
cant human or mouse genes respectively, that are up-regulated or down-
regulated in each reproductive tissue or cell of interest compared to the
non-reproductive tissue with maximal gene expression. Red columns de-
pict the number genes that are up-regulated and blue columns depict
the number genes that are down-regulated. Changes in gene expression
were considered statistically significant for an FDR of less than or equal
to 0.05. The total number of candidate genes are designated by the black
columns. Candidate genes are genes that passed the FDR and TPM ex-
pression value filters.
Additional file 8: Fig. S3. Venn diagrams comparing the overlap
between the candidate male reproductive genes identified by the
indicated reproductive tissues. The human testis combined gene list is
the list of genes from both new samples we isolated and from previously
published testis samples. The human epididymis combined gene list is
the list of genes identified in either previously published samples or the
newly generated samples across all sections of the epididymis. Lastly, the
mouse epididymis combined gene list is the list combined list of genes
identified across all three sections of the mouse epididymis.
Additional file 9: Table S7. Complete cross-sample comparison identi-
fying human and mouse reproductive tract specific genes common to
two or more samples and unique to each as identified through our
studies.
Additional file 10: Fig. S4. Classification of genes into different protein
families and identification of the existence of an experimental mouse
model. Each candidate human gene was classified as an enzyme
(enzyme), chromosome and histone modifiers (epigenetic), G-protein-
coupled receptor (GPCR), orphan G-protein-couple receptor (oGPCR), kin-
ase (kinase), transcription factor (TF), nuclear receptor (NR), ion channel
(IC), chromosome and histone modifying transcript factor (TF; epigenetic),
transporter (transporter) and unknown (A). The total number of candidate
genes identified in our search for mouse models were plotted. Orange
columns designate the number of candidate genes where a model was
identified while yellow designates candidate genes where a model was
not identified (B).
Additional file 11: Table S8. Drug Target Type Classification for
Human Genes. Genes are listed according to the tissue and/or cell that
they were identified as reproductive tract-specific in.
Additional file 12: Table S9. Availability of a Mouse Model for Human
Genes with a Mouse Ortholog. Genes are listed according to the tissue
and/or cell that they were identified as reproductive tract-specific in.
Additional file 13: Fig. S5. One-hundred and forty-two previously iden-
tified human male reproductive tract-specific genes that remain without
a reported mouse model. The listed genes were identified in one or more
datasets as indicated in the Venn diagram. Underlined genes were also
identified in our studies as reproductive tract-specific in mouse. Genes
written in blue encode either enzymes, kinases, GPCRs, oGPCRs, trans-
porters, transcription factors, or proteins involved in epigenetic regulation.
Genes written in dark red were identified in both testis (testis and/or
testis cell) and in epididymis.
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Additional file 14: Fig. S6. Seventy-three human male reproductive
tract-specific genes that each have a reported mouse model with male
infertility phenotype. The listed genes were identified in one or more
datasets as indicated in the Venn diagram. Underlined genes were also
identified in our studies as reproductive tract-specific in mouse. Genes
written in blue encode either enzymes, kinases, GPCRs, oGPCRs, trans-
porters, transcription factors, or proteins involved in epigenetic regulation.
Genes written in dark red were identified in both testis (testis and/or
testis cell) and in epididymis.
Additional file 15: Fig. S7. RT-PCR confirmation of reproductive tract-
specificity in both humans (A) and mice (B). The genes listed in this figure
were identified through our studies and previous studies, but currently
remain without a reported mouse model. GAPDH and Hprt are included
as housekeeping genes.
Additional file 16: Fig. S8. Eighty-nine novel human genes without a
mouse ortholog. The listed genes were identified in one or more datasets
as indicated in the Venn diagram. Genes written in blue encode either
enzymes, kinases, GPCRs, oGPCRs, transporters, transcription factors, or
proteins involved in epigenetic regulation. Genes written in dark red were
identified in both testis (testis and/or testis cell) and in epididymis.
Additional file 17: Fig. S9. Novel reproductive tract-specific human
genes that do not have any equivalent mouse orthologs. These genes
may serve as potential contraceptive targets, however functional valid-
ation would need to be carried out in another model organism than
mouse, such as rat or marmoset, which do have orthologs to these
genes. The digital PCR (heatmap) depicts the average transcripts per mil-
lion (TPM) value per tissue per gene from the indicated human RNA-seq
datasets as processed in parallel through our bioinformatics pipeline.
White = 0 TPM, Black ≥30 TPM. The expression profile of the human
housekeeping gene, GAPDH, is included as reference. For data obtained
from published datasets, superscript values reference the dataset publica-
tion as previously mentioned.
Additional file 18: Table S10. 1064 Previously Identified Genes. Genes
previously identified as male reproductive tract-specific through high
throughput gene expression studies using either microarrays or RNA-seq
[2–8]. The human ortholog to genes identified in mouse and rat studies
is included.
Additional file 19: Fig. S10. Developmental expression pattern of
Spint3, Spint4, Spint5, Pp2d1, and Saxo1 in epididymis and testis of
postnatal and adult mice. Whole epididymides were used at postnatal
days 3, 6, 10, and 14 and epididymis segments (caput, corpus, and cauda)
were used at postnatal days 21, 28, 35, and 60. Whole testes were used
at all time points. The housekeeping gene, Hprt, was used as reference.
Additional file 20: Fig. S11. Multi-channel fluorescence images of bilat-
eral epididymis serial sections stained with custom RNAscope probes tar-
geting either Spint3, Spint4, or Spint5 mRNA (red) and DAPI (blue). The
position of Caput (Cap), Corpus (Cor), and Cauda (Cau) is labeled in the
overview image (left column). The position of the magnification over the
epididymis is the same for all three sections (right column).
Additional file 21: Fig. S12. Representative periodic acid-Schiff staining
of Spint3 and Spint4/5 knockout and littermate control (wild-type) testes
and epididymis segments (caput, corpus, and cauda) at 3 months of age.
Additional file 22: Fig. S13. Representative periodic acid-Schiff staining
of Ces5a knockout and littermate control (wild-type) testes and epididy-
mis segments (caput, corpus, and cauda) at 3 months of age.
Additional file 23: Fig. S14. Representative scanning electron
microscopy images of Spint4/5 and Ces5a KO and littermate control
mouse sperm.
Additional file 24: Fig. S15. Representative periodic acid-Schiff staining
of Pp2d1 and Saxo1 knockout and littermate control (wild-type) testes
and epididymis segments (caput, corpus, and cauda) at 3 months of age.
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